Trial Profile

Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aspirin (Primary) ; Rivaroxaban (Primary)
Indications Acute coronary syndromes; Arterial thrombosis; Atherosclerosis; Cardiovascular disorders; Coronary artery disease; Peripheral arterial disorders
Focus Therapeutic Use
Acronyms XATOA
Sponsors Bayer

23 May 2022 According to a Janssen Pharmaceutical Media Release, results from open label extension part have been published in the European Society of Cardiology's (ESC) European Heart Journal, Cardiovascular Pharmacotherapy.Additionally, the XATOA registry was presented at the American Congress of Cardiology's 71st Annual Scientific Session (ACC.22).
23 May 2022 Results published in the Janssen Pharmaceutical Media Release
03 Aug 2021 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com